BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy

https://doi.org/10.1200/JCO.2016.70.7836

2.

Iacobucci

I

,

Mullighan

CG

.

Genetic basis of acute lymphoblastic leukemia

.

J Clin Oncol

.

2017 Mar 20

;

35

(

9

):

975

–

83

.

.

https://doi.org/10.1182/blood-2015-02-580043

3.

Hunger

SP

,

Mullighan

CG

.

Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine

.

Blood

.

2015 Jun 25

;

125

(

26

):

3977

–

87

.

.

https://doi.org/10.1182/blood-2016-03-643544

4.

Arber

DA

,

Orazi

A

,

Hasserjian

R

,

Thiele

J

,

Borowitz

MJ

,

Le Beau

MM

,

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

.

Blood

.

2016 May 19

;

127

(

20

):

2391

–

405

.

.

https://doi.org/10.1182/asheducation-2018.1.137

5.

Roberts

KG

.

Genetics and prognosis of ALL in children vs adults

.

Hematology Am Soc Hematol Educ Program

.

2018 Nov 30

;

2018

(

1

):

137

–

45

.

.

https://doi.org/10.1056/NEJMra1400972

6.

Hunger

SP

,

Mullighan

CG

.

Acute lymphoblastic leukemia in children

.

N Engl J Med

.

2015 Oct 15

;

373

(

16

):

1541

–

52

.

.

https://doi.org/10.1182/asheducation-2005.1.131

7.

Larson

RA

.

Acute lymphoblastic leukemia: older patients and newer drugs

.

Hematology Am Soc Hematol Educ Program

.

2005

:

131

–

6

.

.

https://doi.org/10.1182/asheducation-2010.1.21

8.

Stock

W

.

Adolescents and young adults with acute lymphoblastic leukemia

.

Hematology Am Soc Hematol Educ Program

.

2010

;

2010

:

21

–

9

.

.

https://doi.org/10.1056/NEJMoa0808253

9.

Mullighan

CG

,

Su

X

,

Zhang

J

,

Radtke

I

,

Phillips

LA

,

Miller

CB

,

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

.

N Engl J Med

.

2009 Jan 29

;

360

(

5

):

470

–

80

.

.

https://doi.org/10.1016/S1470-2045(08)70339-5

10.

den Boer

ML

,

van Slegtenhorst

M

,

de Menezes

RX

,

Cheok

MH

,

Buijs-Gladdines

JG

,

Peters

ST

,

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

.

Lancet Oncol

.

2009 Feb

;

10

(

2

):

125

–

34

.

.

https://doi.org/10.1056/NEJMoa1403088

11.

Roberts

KG

,

Li

Y

,

Payne-Turner

D

,

Harvey

RC

,

Yang

YL

,

Pei

D

,

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

.

N Engl J Med

.

2014 Sep 11

;

371

(

11

):

1005

–

15

.

.

https://doi.org/10.1038/nature06866

12.

Mullighan

CG

,

Miller

CB

,

Radtke

I

,

Phillips

LA

,

Dalton

J

,

Ma

J

,

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

.

Nature

.

2008 May 1

;

453

(

7191

):

110

–

4

.

.

https://doi.org/10.1038/nature05690

13.

Mullighan

CG

,

Goorha

S

,

Radtke

I

,

Miller

CB

,

Coustan-Smith

E

,

Dalton

JD

,

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

.

Nature

.

2007 Apr 12

;

446

(

7137

):

758

–

64

.

.

https://doi.org/10.1200/JCO.2016.69.0073

14.

Roberts

KG

,

Gu

Z

,

Payne-Turner

D

,

McCastlain

K

,

Harvey

RC

,

Chen

IM

,

High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults

.

J Clin Oncol

.

2017 Feb

;

35

(

4

):

394

–

401

.

.

https://doi.org/10.1200/JCO.2014.55.4105

15.

Roberts

KG

,

Pei

D

,

Campana

D

,

Payne-Turner

D

,

Li

Y

,

Cheng

C

,

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease

.

J Clin Oncol

.

2014 Sep 20

;

32

(

27

):

3012

–

20

.

.

https://doi.org/10.1016/j.ccr.2012.06.005

16.

Roberts

KG

,

Morin

RD

,

Zhang

J

,

Hirst

M

,

Zhao

Y

,

Su

X

,

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia

.

Cancer Cell

.

2012 Aug 14

;

22

(

2

):

153

–

66

.

.

https://doi.org/10.3324/haematol.2014.117424

17.

Boer

JM

,

Koenders

JE

,

van der Holt

B

,

Exalto

C

,

Sanders

MA

,

Cornelissen

JJ

,

Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates

.

Haematologica

.

2015 Jul

;

100

(

7

):

e261

–

4

.

.

https://doi.org/10.1182/blood-2016-07-726588

18.

Jain

N

,

Roberts

KG

,

Jabbour

E

,

Patel

K

,

Eterovic

AK

,

Chen

K

,

Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

.

Blood

.

2017 Feb 2

;

129

(

5

):

572

–

81

.

.

https://doi.org/10.1016/j.clml.2017.03.299

19.

Pui

CH

,

Roberts

KG

,

Yang

JJ

,

Mullighan

CG

.

Philadelphia chromosome-like acute lymphoblastic leukemia

.

Clin Lymphoma Myeloma Leuk

.

2017 Aug

;

17

(

8

):

464

–

70

.

.

https://doi.org/10.1016/j.clml.2019.08.003

20.

Owattanapanich

W

,

Rujirachun

P

,

Ungprasert

P

,

Buaboonnam

J

,

Techavichit

P

.

Prevalence and clinical outcome of philadelphia-like acute lymphoblastic leukemia: systematic review and meta-analysis

.

Clin Lymphoma Myeloma Leuk

.

2020 Jan

;

20

(

1

):

e22

–

9

.

.

https://doi.org/10.3324/haematol.2020.247973

21.

Chiaretti

S

,

Messina

M

,

Della Starza

I

,

Piciocchi

A

,

Cafforio

L

,

Cavalli

M

,

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

.

Haematologica

.

2021 Jun 1

;

106

(

6

):

1559

–

68

.

.

https://doi.org/10.1038/s41408-020-0308-3

22.

Sánchez

R

,

Ribera

J

,

Morgades

M

,

Ayala

R

,

Onecha

E

,

Ruiz-Heredia

Y

,

A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics

.

Blood Cancer J

.

2020 Apr 24

;

10

(

4

):

43

.

.

https://doi.org/10.1182/blood-2009-03-208397

23.

Russell

LJ

,

Capasso

M

,

Vater

I

,

Akasaka

T

,

Bernard

OA

,

Calasanz

MJ

,

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia

.

Blood

.

2009 Sep 24

;

114

(

13

):

2688

–

98

.

.

https://doi.org/10.1038/ng.469

24.

Mullighan

CG

,

Collins-Underwood

JR

,

Phillips

LA

,

Loudin

MG

,

Liu

W

,

Zhang

J

,

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia

.

Nat Genet

.

2009 Nov

;

41

(

11

):

1243

–

6

.

.

https://doi.org/10.1073/pnas.0911726107

25.

Yoda

A

,

Yoda

Y

,

Chiaretti

S

,

Bar-Natan

M

,

Mani

K

,

Rodig

SJ

,

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia

.

Proc Natl Acad Sci U S A

.

2010 Jan 5

;

107

(

1

):

252

–

7

.

.

https://doi.org/10.1182/bloodadvances.2019000163

26.

Harvey

RC

,

Tasian

SK

.

Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia

.

Blood Adv

.

2020 Jan 14

;

4

(

1

):

218

–

28

.

.

https://doi.org/10.1016/j.anndiagpath.2021.151767

27.

Thakral

B

,

Jain

N

,

Tang

G

,

Konoplev

S

,

Vega

F

,

Medeiros

LJ

,

From the archives of MD Anderson Cancer Center: concurrent BCR-ABL1 and CRLF2 rearrangements in B-lymphoblast phase of chronic myeloid leukemia

.

Ann Diagn Pathol

.

2021 Jun 5

;

53

:

151767

.

.

https://doi.org/10.1371/journal.pone.0220026

28.

Meyer

LK

,

Delgado-Martin

C

,

Maude

SL

,

Shannon

KM

,

Teachey

DT

,

Hermiston

ML

.

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition

.

PLoS One

.

2019

;

14

(

7

):

e0220026

.

.

https://doi.org/10.1182/blood-2018-10-881961

29.

Stock

W

,

Luger

SM

,

Advani

AS

,

Yin

J

,

Harvey

RC

,

Mullighan

CG

,

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

.

Blood

.

2019 Apr 4

;

133

(

14

):

1548

–

59

.

.

https://doi.org/10.18632/oncotarget.25411

30.

Pastorczak

A

,

Sedek

L

,

Braun

M

,

Madzio

J

,

Sonsala

A

,

Twardoch

M

,

Surface expression of cytokine receptor-like factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions

.

Oncotarget

.

2018 May 25

;

9

(

40

):

25971

–

82

.

.

31.

Shochat

C

,

Tal

N

,

Bandapalli

OR

,

Palmi

C

,

Ganmore

I

,

te Kronnie

G

,

Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias

.

J Exp Med

.

2011 May 9

;

208

(

5

):

901

–

8

.

https://doi.org/10.3324/haematol.2018.192088

32.

Ding

YY

,

Stern

JW

,

Jubelirer

TF

,

Wertheim

GB

,

Lin

F

,

Chang

F

,

Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with GOLGA5-JAK2 fusion and induction failure

.

Haematologica

.

2018 Sep

;

103

(

9

):

e427

–

31

.

.

https://doi.org/10.1182/blood-2012-03-415448

33.

Maude

SL

,

Tasian

SK

,

Vincent

T

,

Hall

JW

,

Sheen

C

,

Roberts

KG

,

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

.

Blood

.

2012 Oct 25

;

120

(

17

):

3510

–

8

.

.

https://doi.org/10.18632/oncotarget.24261

34.

Zhang

Q

,

Shi

C

,

Han

L

,

Jain

N

,

Roberts

KG

,

Ma

H

,

Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia

.

Oncotarget

.

2018 Jan 30

;

9

(

8

):

8027

–

41

.

.

https://doi.org/10.1182/blood-2014-11-612903

35.

Qin

H

,

Cho

M

,

Haso

W

,

Zhang

L

,

Tasian

SK

,

Oo

HZ

,

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein

.

Blood

.

2015 Jul 30

;

126

(

5

):

629

–

39

.

.

https://doi.org/10.1182/blood-2015-06-650812

36.

Davies

DM

,

Maher

J

.

TSLPR: a new CAR in the showroom for B-ALL

.

Blood

.

2015 Jul 30

;

126

(

5

):

567

–

9

.

.

https://doi.org/10.1093/ajcp/aqx005

37.

Konoplev

S

,

Lu

X

,

Konopleva

M

,

Jain

N

,

Ouyang

J

,

Goswami

M

,

CRLF2-positive B-cell acute lymphoblastic leukemia in adult patients: a single-institution experience

.

Am J Clin Pathol

.

2017 Apr 1

;

147

(

4

):

357

–

63

.

.

https://doi.org/10.1634/theoncologist.2018-0272

38.

Severson

EA

,

Vergilio

JA

,

Gay

LM

,

Daniel

S

,

Hemmerich

AC

,

Elvin

JA

,

Genomic landscape of adult and pediatric BCR-ABL1-like B-lymphoblastic leukemia using parallel DNA and RNA sequencing

.

Oncologist

.

2019 Mar

;

24

(

3

):

372

–

4

.

.

https://doi.org/10.1002/pbc.25327

39.

Kobayashi

K

,

Miyagawa

N

,

Mitsui

K

,

Matsuoka

M

,

Kojima

Y

,

Takahashi

H

,

TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation

.

Pediatr Blood Cancer

.

2015 Jun

;

62

(

6

):

1058

–

60

.

.

https://doi.org/10.18632/oncotarget.24020

40.

Gotesman

M

,

Vo

TT

,

Herzog

LO

,

Tea

T

,

Mallya

S

,

Tasian

SK

,

mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL

.

Oncotarget

.

2018 Jan 19

;

9

(

5

):

6562

–

71

.

.

https://doi.org/10.18632/oncotarget.13492

41.

Boer

JM

,

Steeghs

EM

,

Marchante

JR

,

Boeree

A

,

Beaudoin

JJ

,

Beverloo

HB

,

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia

.

Oncotarget

.

2017 Jan 17

;

8

(

3

):

4618

–

28

.

.

https://doi.org/10.1182/blood-2011-12-389932

42.

Tasian

SK

,

Doral

MY

,

Borowitz

MJ

,

Wood

BL

,

Chen

IM

,

Harvey

RC

,

Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia

.

Blood

.

2012 Jul 26

;

120

(

4

):

833

–

42

.

.

43.

Ohki

K

,

Takahashi

H

,

Fukushima

T

,

Nanmoku

T

,

Kusano

S

,

Mori

M

,

Impact of immunophenotypic characteristics on genetic subgrouping in childhood acute lymphoblastic leukemia: Tokyo Children’s Cancer Study Group (TCCSG) study L04-16

.

Genes Chromosomes Cancer

.

2020 Oct

;

59

(

10

):

551

–

61

.

https://doi.org/10.1002/ajh.25126

44.

Siegele

BJ

,

Nardi

V

.

Laboratory testing in BCR-ABL1-like (Philadelphia-like) B-lymphoblastic leukemia/lymphoma

.

Am J Hematol

.

2018 Jul

;

93

(

7

):

971

–

7

.

.

https://doi.org/10.5858/arpa.2019-0194-RA

45.

Jain

S

,

Abraham

A

.

BCR-ABL1-like B-acute lymphoblastic leukemia/lymphoma: a comprehensive review

.

Arch Pathol Lab Med

.

2020 Feb

;

144

(

2

):

150

–

5

.

.

https://doi.org/10.1002/cncr.31848

46.

Chiaretti

S

,

Messina

M

,

Foà

R

.

BCR/ABL1-like acute lymphoblastic leukemia: how to diagnose and treat?

Cancer

.

2019 Jan 15

;

125

(

2

):

194

–

204

.

.

47.

Harvey

RC

,

Kang

H

,

Roberts

KG

,

Chen

I-ML

,

Atlas

SR

,

Bedrick

EJ

,

Development and validation of a highly sensitive and specific gene expression classifier to prospectively screen and identify B-precursor acute lymphoblastic leukemia (ALL) patients with a Philadelphia chromosome-like (“Ph-like” or “BCR-ABL1-Like”) signature for therapeutic targeting and clinical intervention

.

Blood

.

2013 Nov 15

;

122

(

21

):

826

.

https://doi.org/10.3324/haematol.2016.162925

48.

Heatley

SL

,

Sadras

T

,

Kok

CH

,

Nievergall

E

,

Quek

K

,

Dang

P

,

High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment

.

Haematologica

.

2017 Dec

;

102

(

12

):

e490

–

3

.

.

49.

Roberts

KG

,

Reshmi

SC

,

Harvey

RC

,

Chen

I-M

,

Patel

K

,

Stonerock

E

,

Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group

.

Blood

.

2018 Aug 23

;

132

(

8

):

815

–

24

.

https://doi.org/10.1111/bjh.15251

50.

Chiaretti

S

,

Messina

M

,

Grammatico

S

,

Piciocchi

A

,

Fedullo

AL

,

Di Giacomo

F

,

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications

.

Br J Haematol

.

2018 Jun

;

181

(

5

):

642

–

52

.

.

https://doi.org/10.1182/asheducation-2016.1.561

51.

Tran

TH

,

Loh

ML

.

Ph-like acute lymphoblastic leukemia

.

Hematology Am Soc Hematol Educ Program

.

2016 Dec 2

;

2016

(

1

):

561

–

6

.

.

52.

Reshmi

SC

,

Harvey

RC

,

Roberts

KG

,

Stonerock

E

,

Smith

A

,

Jenkins

H

,

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children’s Oncology Group

.

Blood

.

2017 Jun 22

;

129

(

25

):

3352

–

61

.

https://doi.org/10.1007/s12288-018-0997-y

53.

Fasan

A

,

Kern

W

,

Nadarajah

N

,

Weber

S

,

Schindela

S

,

Schlenther

N

,

Paper: three steps to the diagnosis of adult Ph-like ALL [Internet]

. [cited 2021 Jun 16]. Available from: https://ash.confex.com/ash/2015/webprogramscheduler/Paper79722.html.

54.

Totadri

S

,

Singh

M

,

Trehan

A

,

Varma

N

,

Bhatia

P

.

Keeping PACE with Ph positive to Ph-Like detection in B-lineage acute lymphoblastic leukemia: a practical and cost effective (PACE) approach in a resource constrained setting

.

Indian J Hematol Blood Transfus

.

2018 Oct

;

34

(

4

):

595

–

601

.

.

https://doi.org/10.1080/10428194.2016.1219902

55.

Yap

KL

,

Furtado

LV

,

Kiyotani

K

,

Curran

E

,

Stock

W

,

McNeer

JL

,

Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL)

.

Leuk Lymphoma

.

2017 Apr

;

58

(

4

):

950

–

8

.

.

https://doi.org/10.1016/j.beha.2021.101242

56.

Aldoss

I

,

Advani

AS

.

Have any strategies in Ph-like ALL been shown to be effective?

Best Pract Res Clin Haematol

.

2021 Mar

;

34

(

1

):

101242

.

.

https://doi.org/10.1016/j.bbmt.2018.09.041

57.

Aldoss

I

,

Kamal

MO

,

Forman

SJ

,

Pullarkat

V

.

Adults with Philadelphia chromosome-like acute lymphoblastic leukemia: considerations for allogeneic hematopoietic cell transplantation in first complete remission

.

Biol Blood Marrow Transplant

.

2019 Feb

;

25

(

2

):

e41

–

5

.

.

https://doi.org/10.1016/j.bbmt.2019.08.010

58.

El Fakih

R

,

Savani

B

,

Mohty

M

,

Aljurf

M

.

Hematopoietic cell transplant consideration for Philadelphia chromosome-like acute lymphoblastic leukemia patients

.

Biol Blood Marrow Transplant

.

2020 Jan

;

26

(

1

):

e16

–

20

.

.

59.

Cho

H

,

Kim

Y

,

Yoon

J-H

,

Lee

J

,

Lee

GD

,

Son

J

,

Non-inferior long-term outcomes of adults with Philadelphia chromosome-like acute lymphoblastic leukemia

.

Bone Marrow Transplant

.

2021 Apr 6

;

56

:

1953

–63.

https://doi.org/10.1182/blood-2016-05-707653

60.

Tasian

SK

,

Teachey

DT

,

Li

Y

,

Shen

F

,

Harvey

RC

,

Chen

IM

,

Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia

.

Blood

.

2017 Jan 12

;

129

(

2

):

177

–

87

.

.

https://doi.org/10.3324/haematol.2015.136499

61.

Duployez

N

,

Grzych

G

,

Ducourneau

B

,

Alarcon Fuentes

M

,

Grardel

N

,

Boyer

T

,

NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors

.

Haematologica

.

2016 Apr

;

101

(

4

):

e133

–

4

.

.

62.

Jain

N

,

Jabbour

EJ

,

McKay

PZ

,

Ravandi

F

,

Takahashi

K

,

Kadia

T

,

Ruxolitinib or dasatinib in combination with chemotherapy for patients with relapsed/refractory Philadelphia (Ph)-like acute lymphoblastic leukemia: a phase I–II trial

.

Blood

.

2017 Dec 7

;

130

(

Supplement 1

):

1322

.

63.

Bӧhm

JW

,

Sia

KCS

,

Jones

C

,

Evans

K

,

Mariana

A

,

Pang

I

,

Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia

.

Leukemia

.

2021 Apr 24

.

https://doi.org/10.1182/bloodadvances.2017011296

64.

Roberts

KG

,

Yang

YL

,

Payne-Turner

D

,

Lin

W

,

Files

JK

,

Dickerson

K

,

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL

.

Blood Adv

.

2017 Sep 12

;

1

(

20

):

1657

–

71

.

.

https://doi.org/10.1002/pbc.26328

65.

Mayfield

JR

,

Czuchlewski

DR

,

Gale

JM

,

Matlawska-Wasowska

K

,

Vasef

MA

,

Nickl

C

,

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia

.

Pediatr Blood Cancer

.

2017 May

;

64

(

5

):

10.1002/pbc.26328

.

.

https://doi.org/10.1111/petr.14024

66.

Bayram

N

,

Yaman

Y

,

Özdilli

K

,

Telhan

L

,

Nepesov

S

,

Bilgen

H

,

Clinical efficacy of ruxolitinib monotherapy and haploidentical hematopoeitic stem cell transplantation in a child with Philadelphia chromosome-like relapsed/refractory acute lymphoblastic leukemia

.

Pediatr Transplant

.

2021 Jun

;

25

(

4

):

e14024

.

.

https://doi.org/10.1200/JCO.2012.47.6770

67.

Weston

BW

,

Hayden

MA

,

Roberts

KG

,

Bowyer

S

,

Hsu

J

,

Fedoriw

G

,

Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia

.

J Clin Oncol

.

2013 Sep 1

;

31

(

25

):

e413

–

6

.

.

https://doi.org/10.3389/fonc.2020.00359

68.

Dai

HP

,

Yin

J

,

Li

Z

,

Yang

CX

,

Cao

T

,

Chen

P

,

Rapid molecular response to dasatinib in a pediatric relapsed acute lymphoblastic leukemia with NCOR1-LYN fusion

.

Front Oncol

.

2020

;

10

:

359

.

.

https://doi.org/10.12659/ajcr.906300

69.

Zhang

G

,

Zhang

Y

,

Wu

J

,

Chen

Y

,

Ma

Z

.

Acute lymphoblastic leukemia patient with variant ATF7IP/PDGFRB fusion and favorable response to tyrosine kinase inhibitor Treatment: a case report

.

Am J Case Rep

.

2017 Nov 14

;

18

:

1204

–

8

.

.

https://doi.org/10.1080/10428194.2019.1668938

70.

Fazio

F

,

Barberi

W

,

Cazzaniga

G

,

Fazio

G

,

Messina

M

,

Della Starza

I

,

Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript

.

Leuk Lymphoma

.

2020 Feb

;

61

(

2

):

469

–

72

.

.

https://doi.org/10.1158/2159-8290.CD-20-1465

71.

Pullarkat

VA

,

Lacayo

NJ

,

Jabbour

E

,

Rubnitz

JE

,

Bajel

A

,

Laetsch

TW

,

Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma

.

Cancer Discov

.

2021 Jun 1

;

11

(

6

):

1440

–

53

.

.

https://doi.org/10.1182/blood-2006-03-011908

72.

Aldoss

I

,

Afkhami

M

,

Yang

D

,

Mokhtari

S

,

Tomasian

V

,

Gu

Z

,

Favorable outcomes after novel therapies for relapse/refractory Philadelphia-like acute lymphoblastic leukemia

.

EHA Library

. In [cited 2021 Jul 3]. Available from: https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/325105/ibrahim.aldoss.favorable.outcomes.after.novel.therapies.for.relapse.refractory.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Dblinatumomab.

73.

de Labarthe

A

,

Rousselot

P

,

Huguet-Rigal

F

,

Delabesse

E

,

Witz

F

,

Maury

S

,

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study

.

Blood

.

2007 Feb 15

;

109

(

4

):

1408

–

13

.

.